With active partnerships across 3 continents with more than 40 top-tier academic partners and a diverse cohort of investors, Evotec’s BRIDGEs have become a globally leading pre-seed accelerator initiative.
Alongside operational BRIDGE-building, our team has also been reflecting conceptually on the challenges and best practices in accelerating the transition from an academic starting point in drug discovery to an investable proof of concept.
Key thoughts are now summarized in our whitepaper mini-series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’
In three chapters we share openly our insights and views to inspire a continued dialogue between academic researchers, investors, and biotech and pharma colleagues on how to build an even more robust translational community and – together, for medicines that matter - develop new first-in-class therapies and platforms.
Download the free content!
Visit our Academic BRIDGEs website page
Discuss your project with us: